年轻男性乳房发育症存在偶然病理发现,病检是否该作为常规检查?

2022-03-24 MedSci原创 MedSci原创

对成年男性乳房发育症人群进行的大规模研究表明,偶发性病理学发现的发病率较低,但可明显提高乳腺癌的风险。鉴于该人群中乳腺癌的发病率较低,对年轻男性乳房组织的病理检查存在争议。

对成年男性乳房发育症人群进行的大规模研究表明,偶发性病理学发现的发病率较低,但可明显提高乳腺癌的风险。鉴于该人群中乳腺癌的发病率较低,对年轻男性乳房组织的病理检查存在争议。

图1 文章来源

研究者检查了一大群患有男性乳房发育症的青少年的病理结果,回顾性分析2007年2月至2019年11月在一家机构接受单侧或双侧乳腺切除术治疗女性乳腺增生症的男性患者的人口统计学、病史、手术特征和病理结果,以评估对该人群进行常规组织分析的必要性。

该研究共纳入268例男性患者。平均年龄为16.6岁。平均体重指数为27.8 kg/m2,42.5%的样本为肥胖。结果显示,大多数(83.2%)接受了双侧皮下切除术。95.1%的患者无异常组织病理学表现。在13例异常患者中,8例(3%)为非增生性病变,2例(0.8%)为增生性病变,无非典型性,2例(0.8%)为不典型导管增生,1例(0.4%)为双侧不典型导管增生和单侧导管原位癌。没有患者患有浸润性癌。三名患有非典型导管增生和/或导管原位癌的患者肥胖,但没有其他乳腺癌或女性乳腺癌风险因素。

表1年轻男性非典型性增生性病变或导管原位癌的详细发现

在三名男性青少年(1.2%)中发现了可能增加患乳腺癌风险的发现。潜在风险增加的病理发现的比率,特别是增生伴异型性和导管原位癌,在男性和女性青少年之间是相似的。在这一人群中,放弃男性乳房畸形标本的争论包括:侵袭性癌症的罕见性、对许多患者的直接成本负担,以及男性乳房畸形矫正的潜在治疗性质,因为在这些手术过程中,绝大多数腺体组织被切除。

尽管令人担忧的病理学结果很少,但对年轻男性不典型增生和导管原位癌的自然史知之甚少,因此建议不要进行常规分析。

 

原始文章:

Maroney, Jenna, Dannheim, Katelyn, Hollowell, Monica, Labow, Brian, Rogers-Vizena, Carolyn. Incidental Pathologic Findings in Young Men with Gynecomastia. Plast Reconstr Surg. 2022;149(3):608-613. doi:10.1097/PRS.0000000000008815.

评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1943043, encodeId=38d019430435f, content=<a href='/topic/show?id=8832489889d' target=_blank style='color:#2F92EE;'>#年轻男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48988, encryptionId=8832489889d, topicName=年轻男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Feb 14 08:25:39 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347610, encodeId=8358134e610fb, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516513, encodeId=0d7a151651324, content=<a href='/topic/show?id=482223624f0' target=_blank style='color:#2F92EE;'>#乳房发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23624, encryptionId=482223624f0, topicName=乳房发育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=529d10977415, createdName=12498dabm80暂无昵称, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205538, encodeId=6aeb12055386a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abd26569671, createdName=ms4000000908312148, createdTime=Thu Mar 24 12:18:25 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1943043, encodeId=38d019430435f, content=<a href='/topic/show?id=8832489889d' target=_blank style='color:#2F92EE;'>#年轻男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48988, encryptionId=8832489889d, topicName=年轻男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Feb 14 08:25:39 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347610, encodeId=8358134e610fb, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516513, encodeId=0d7a151651324, content=<a href='/topic/show?id=482223624f0' target=_blank style='color:#2F92EE;'>#乳房发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23624, encryptionId=482223624f0, topicName=乳房发育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=529d10977415, createdName=12498dabm80暂无昵称, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205538, encodeId=6aeb12055386a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abd26569671, createdName=ms4000000908312148, createdTime=Thu Mar 24 12:18:25 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-25 neurowu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1943043, encodeId=38d019430435f, content=<a href='/topic/show?id=8832489889d' target=_blank style='color:#2F92EE;'>#年轻男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48988, encryptionId=8832489889d, topicName=年轻男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Feb 14 08:25:39 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347610, encodeId=8358134e610fb, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516513, encodeId=0d7a151651324, content=<a href='/topic/show?id=482223624f0' target=_blank style='color:#2F92EE;'>#乳房发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23624, encryptionId=482223624f0, topicName=乳房发育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=529d10977415, createdName=12498dabm80暂无昵称, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205538, encodeId=6aeb12055386a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abd26569671, createdName=ms4000000908312148, createdTime=Thu Mar 24 12:18:25 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1943043, encodeId=38d019430435f, content=<a href='/topic/show?id=8832489889d' target=_blank style='color:#2F92EE;'>#年轻男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48988, encryptionId=8832489889d, topicName=年轻男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Tue Feb 14 08:25:39 CST 2023, time=2023-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347610, encodeId=8358134e610fb, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1516513, encodeId=0d7a151651324, content=<a href='/topic/show?id=482223624f0' target=_blank style='color:#2F92EE;'>#乳房发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23624, encryptionId=482223624f0, topicName=乳房发育)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=529d10977415, createdName=12498dabm80暂无昵称, createdTime=Fri Mar 25 07:25:39 CST 2022, time=2022-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1205538, encodeId=6aeb12055386a, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=abd26569671, createdName=ms4000000908312148, createdTime=Thu Mar 24 12:18:25 CST 2022, time=2022-03-24, status=1, ipAttribution=)]
    2022-03-24 ms4000000908312148

    #学习#不错

    0

相关资讯

Eur J Cancer:卡培他滨辅助治疗对乳腺癌患者生存预后的影响

卡培他滨可改善三阴性乳腺癌患者的无病生存预后和总生存预后,加入系统治疗时还可改善所有早期乳腺癌患者的无病生存预后和总生存预后

Cancers:世界首创!小分子药物可抑制人类乳腺癌复发和转移

乳腺癌,是女性中最常见的癌症,在神刊 CA 2021年癌症统计报告中显示,乳腺癌已成为女性三大癌症之首,仅乳腺癌就占女性癌症的30%。而在中国,乳腺癌的发病率也在逐年提升。

European Radiology:DW MRI在预测乳腺癌新辅助化疗早期反应中的价值

目前,新辅助化疗(NAC)已广泛用于乳腺癌的治疗。新辅助化疗通常应用于患有局部晚期乳腺癌和炎症性乳腺癌的患者中国,可降低肿瘤的分期以便进行保乳手术。

Nature Cell Biology:亮氨酸tRNA合成酶是乳腺癌的肿瘤抑制因子

癌症因其复杂性和难治性,一直是医学界的一道难以跨越的天堑。癌症的发生与许多因素相关,从分子生物学的角度来看,肿瘤的发生发展都涉及转录组和翻译组的改变,但与转录控制不同,翻译控制在癌症中的研究较少。

良好的术前心理竟然可以减少乳房重建术后并发症

心理因素被广泛理解为有助于整体健康,但它们对伤口愈合的作用还没有很好地定义。术前身体形象等心理因素与术后并发症的相关性资料有限。

选择性雌激素受体降解剂 (SERD) amcenestrant 治疗乳腺癌,未能达到主要终点

赛诺菲近日宣布对其实验性选择性雌激素受体降解剂 (SERD) amcenestrant 的 II 期研究未能达到其改善某些乳腺癌患者的无进展生存期 (PFS) 的主要终点。

拓展阅读

乳腺癌术后复发风险分组及全身辅助治疗选择

乳腺癌术后复发风险分组及全身辅助治疗选择,点击即可查看别错过。

HR阳性HER2扩增转移性乳腺癌接受德曲妥珠单抗治疗后复发,获益奈拉替尼三联方案

本研究报告一例HR+/HER2扩增型转移性乳腺癌患者:该患者接受德曲妥珠单抗治疗后获得接近完全缓解,但约 9 个月后出现疾病进展。

Adv Sci:陆军军医大学高铭萱等研究开发了一种用于高灵敏度检测乳腺癌患者外周血中的DNMT1活性的反应体系

该研究开发了一种名为“DNMT1活性识别”(DIVA)的反应体系,用于高灵敏度检测乳腺癌患者外周血中的DNMT1活性。

European Radiology:在非肿块增强病变中预测乳腺癌的多变量模型

近年来,研究人员对探索提高非肿块样强化病变诊断效率的方法表现出越来越浓厚的兴趣。

JCO | 帕博西尼联合内分泌治疗未显著改善HR+/HER2-晚期乳腺癌PFS:PALMIRA试验结果

PALMIRA试验旨在评估帕博西尼重新挑战联合二线内分泌治疗在一线帕博西尼为基础的内分泌治疗进展后的激素受体阳性/HER2阴性ABC患者中的抗肿瘤活性,结果显示该研究未达到其主要目标。

乳腺癌步入“慢病”时代,徐兵河院士详解乳腺癌防治要点

【医悦汇】特邀中国工程院徐兵河院士做客“科普ONCO”栏目,分享乳腺癌防治前沿观点。

2025 AGO建议:局部晚期和转移性乳腺癌的诊断和治疗(更新版)

德国妇科肿瘤小组(AGO,German Gynecological Oncology Group) · 2025-02-08

2025 ASCO指南更新:早期乳腺癌前哨淋巴结活检

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2025-04-10

2025 AGO建议:早期乳腺癌患者的诊断与治疗(更新版)

德国妇科肿瘤小组(AGO,German Gynecological Oncology Group) · 2025-04-08